Compare IDEXX Laboratories, Inc. (IDXX) vs WD 40 Company (WDFC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs WD 40 Company — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while WD 40 Company trades at $202.29 (market cap $2.73B). The key difference: IDEXX Laboratories, Inc. is far larger — about 14.8× WD 40 Company's market cap, and WD 40 Company pays a 2% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and WD 40 Company for 22 Days on average.
| IDXX | WDFC | |
|---|---|---|
Market Cap | $40.43B | $2.73B |
Volume | 692,164 | 130,665 |
Sector | Health | Basic Materials |
52-Week High | $766.68 | $264.91 |
52-Week Low | $504.70 | $187.52 |
Typical Hold Time | 46 Days | 22 Days |
Enterprise Value | $41.32B | $2.79B |
Dividend Yield | — | 2% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
WDFC trades at $202.29, showing modest daily gains. The technical outlook is bullish, supported by moving averages, while recent earnings have largely beaten expectations. The company maintains strong profitability with a 13.22% net income margin and a 33.22% ROE, though valuation multiples like a P/E of 30.96 appear elevated. Positive news highlights strategic growth initiatives and institutional buying interest.
The stock presents a mixed outlook; robust fundamentals and growth strategy support upside, but high valuation and margin pressures from input costs pose risks. Analyst consensus is cautious with a majority hold rating, indicating balanced but not aggressive investor sentiment near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About WD 40 Company
WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →
